Argent BioPharma shares begin trading on OTCQB Venture Market

(Alliance News) - Argent BioPharma Ltd on Tuesday celebrated the approval of its shares to ...

Alliance News 7 May, 2024 | 1:21PM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - Argent BioPharma Ltd on Tuesday celebrated the approval of its shares to trading in the US, and also announced the appointment of its new chief financial officer.

Argent is a drug discovery company within the biopharmaceutical sector.

Its shares have been approved to trade on the OTCQB Venture Market, and began doing so last Thursday under the ticker 'MGCLF'.

According to Chief Executive Officer Roby Zomer, cross-trading on the OTCQB "will increase liquidity and significantly enhance the ability of US based investors to access and trade Argent BioPharma's shares during a period in which we are actively progressing our key drug development."

"Trading on OTCQB will also, we believe, serve to diversify the share register and increase exposure to a broader range of investors," Zomer added.

Also on Tuesday, Argent announced that it has appointed Igor Bluvstein as chief financial officer. Bluvstein previously served as the CFO at MDD Group.

Shares in Argent BioPharma were down 7.0% at 20.00 pence each in London on Tuesday afternoon.

By Holly Beveridge, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures